Western Blot: MGMT Antibody (MT 23.2) [NB100-168] - Analysis of MGMT (MT 23.2) antibody (NB100-168) - Detection of MGMT in MCF7 lysate using NB100-168 at 1:1000 dilution.
Immunocytochemistry/ Immunofluorescence: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT (Green) in Hela cells using NB100-168 at a 1:50 dilution. Nuclei (Blue) are counterstained using Hoechst 33258.
Immunocytochemistry/ Immunofluorescence: MGMT Antibody (MT 23.2) [NB100-168] - MCF7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were ...read more
Simple Western: MGMT Antibody (MT 23.2) [NB100-168] - Simple Western lane view shows a specific band for MGMT in 0.2 mg/ml of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa ...read more
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.02% Sodium Azide
Protein G purified
This MGMT (MT 23.2) antibody is useful for Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry on paraffin-embedded sections and Western Blot. In WB, a band at ~24 kDa can be seen. In ICC/IF, strong staining has been seen in CEM cells and no signal has been seen in TK6 cells.In Simple Western only 10-15 uL of the recommended dilution is used per data point.
The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
MGMT (6-O-methylguanine-DNA methyltransferase) is a DNA repair enzyme with the ability to protect cells from carcinogenic effects of alkylating agents by removing adducts from the O(6) position of guanine. MGMT repairs alkylated guanine residues in DNA by stoichiometrically transferring the alkyl group at the O-6 position to a cysteine residue in the enzyme, and in this so called 'suicidal reaction', the enzyme is irreversibly inactivated. Localized in the nucleus, MGMT is ubiquitously expressed in normal human tissues with overexpression observed in several types of cancerous cells wherein it provides resistance against alkylating drugs. Howeverit is found epigenetically silenced in some cancers that include lymphoma, breast and prostate cancer, as well as retinoblastoma, wherein this silencing is thought to be due to promoter methylation which interferes with transcriptional factors binding. Indeed, MGMT silencing has been linked to mutations in other tumor-related genes including silencing of p53 (non-small cell lung cancer and astrocytic tumors), k-ras gene mutations (gastric and colorectal cancer), and methylation of CDKN1A gene (encodes p21) as well as CDKN2A gene (encodes p16).
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Doll C, Craighead P, Lees-Miller S, Demetrick D, Eliasziw M, Magliocco A. Expression of Mgmt in Cervical Cancer: a Potential Biomarker for Response to Radiation in Cervical Cancer. 21st Annual Scientific Meeting of the Canadian Association of Radiation Oncologists joint with Canadian Organization of Medical; Toronto; Canada. 9-Oct-07.